Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran in systemic and cutaneous lupus erythematosus
NCT05162586Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Mar 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (8 cohorts), sponsored by EMD Serono. Primary endpoints: Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity at 16 weeks and British Isles Lupus Assessment Group-Based Composite Lupus Assessment at 24 weeks. Started Mar 2022; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05162586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162586.